Skip to main
ABVX
ABVX logo

Abivax SA (ABVX) Stock Forecast & Price Target

Abivax SA (ABVX) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 25%
Buy 75%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Abivax SA's obefazimod has demonstrated strong efficacy and safety profiles in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis, reinforcing the drug's potential for significant market penetration. The data highlights that both tested doses met regulatory endpoints, prompting an increase in peak sales estimates and penetration rates from 20% to 22%. Additionally, the favorable performance of obefazimod in patients with prior treatment failures enhances its competitive advantage and underscores the drug's promising financial outlook.

Bears say

Abivax SA's stock outlook is negatively impacted by the company's ongoing history of financial losses, indicating a lack of profitability and solid operational foundation. The low success bar set by previous oral therapies highlights concerns regarding the efficacy of its drug candidate obefazimod, which may struggle to establish a competitive edge in the market. Furthermore, uncertainties surrounding potential partnerships for commercialization could jeopardize the launch success and overall financial viability of the company.

Abivax SA (ABVX) has been analyzed by 8 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 75% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Abivax SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Abivax SA (ABVX) Forecast

Analysts have given Abivax SA (ABVX) a Buy based on their latest research and market trends.

According to 8 analysts, Abivax SA (ABVX) has a Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $109.12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $109.12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Abivax SA (ABVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.